clinical trial · NCT06481891
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Obstructive Cardiomyopathy, HypertrophicNon-obstructive Hypertrophic CardiomyopathySotagliflozinPlacebo
brief summary
The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.
started
Sep 24, 2024
primary completion
Jan 1, 2027
completion
Feb 1, 2027
last updated
Aug 26, 2026
official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic Obstructive And Non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol